Cancers, Vol. 12, Pages 540: MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma

Conclusions: So far, we found no reliable predictive marker for patients who develop hyperprogression on ICI, specifically with regard to MDM2/4 or EGFR amplifications. Nevertheless, patients with anorectal melanoma, liver metastases or melanoma with amplified MYC seem to have an increased risk of not benefitting from ICI.

Source: Cancers - February 25, 2020 Category: Cancer & Oncology Authors: Forschner Hilke Bonzheim Gschwind Demidov Amaral Ossowski Riess Schroeder Martus Klumpp Gonzalez-Menendez Garbe Niessner Sinnberg Tags: Article Source Type: research